These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 16394363)

  • 1. Generalized hypopigmentation due to imatinib: a fairness boon?
    Sharma A; Vora A; Bhutani M
    Indian J Dermatol Venereol Leprol; 2005; 71(1):45-6. PubMed ID: 16394363
    [No Abstract]   [Full Text] [Related]  

  • 2. Imatinib (STI-571)-induced exfoliative dermatitis in a Saudi patient with deck chair sign.
    Banka N; Aljurf M; Hamadah I
    Dermatology; 2003; 207(3):329-30. PubMed ID: 14571082
    [No Abstract]   [Full Text] [Related]  

  • 3. Hypopigmentation in an African patient treated with imatinib mesylate: a case report.
    Hasan S; Dinh K; Lombardo F; Dawkins F; Kark J
    J Natl Med Assoc; 2003 Aug; 95(8):722-4. PubMed ID: 12934870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous Lichenoid dermatitis associated with imatinib mesylate.
    Chan CY; Browning J; Smith-Zagone MJ; Martinelli PT; Hsu S
    Dermatol Online J; 2007 May; 13(2):29. PubMed ID: 17498448
    [No Abstract]   [Full Text] [Related]  

  • 5. Hypopigmentation from imatinib mesylate (Gleevec).
    Grossman WJ; Wilson DB
    J Pediatr Hematol Oncol; 2004 Mar; 26(3):214. PubMed ID: 15125619
    [No Abstract]   [Full Text] [Related]  

  • 6. Severe tumor lysis syndrome during treatment with STI 571 in a patient with chronic myelogenous leukemia accelerated phase.
    Vora A; Bhutani M; Sharma A; Raina V
    Ann Oncol; 2002 Nov; 13(11):1833-4. PubMed ID: 12419759
    [No Abstract]   [Full Text] [Related]  

  • 7. Challenges in oncology. Case 3. Depigmentation in a chronic myeloid leukemia patient treated with STI-571.
    Raanani P; Goldman JM; Ben-Bassat I
    J Clin Oncol; 2002 Feb; 20(3):869-70. PubMed ID: 11821474
    [No Abstract]   [Full Text] [Related]  

  • 8. Imatinib induced Stevens-Johnson syndrome: lack of recurrence following re-challenge with a lower dose.
    Pavithran K; Thomas M
    Indian J Dermatol Venereol Leprol; 2005; 71(4):288-9. PubMed ID: 16394445
    [No Abstract]   [Full Text] [Related]  

  • 9. Response assessment of patients with chronic myeloid leukemia receiving imatinib mesylate (Glivec) therapy: experience from a single center in a developing country.
    Medhi K; Raina V; Kumar L; Sharma A; Bakhshi S; Gupta R; Kumar R
    Leuk Lymphoma; 2010 Oct; 51(10):1850-4. PubMed ID: 20849386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypopigmentation of the skin due to imatinib mesylate in patients with chronic myeloid leukemia.
    Aleem A
    Hematol Oncol Stem Cell Ther; 2009; 2(2):358-61. PubMed ID: 20118061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib mesylate induced skin hypopigmentation.
    Talwar V; Doval DC; Bhatia K
    J Assoc Physicians India; 2007 Jul; 55():527. PubMed ID: 17907508
    [No Abstract]   [Full Text] [Related]  

  • 12. Successful management of liver injury caused by imatinib mesylate in a patient with previously untreated chronic myelogenous leukemia in the chronic phase.
    Yamazaki R; Okamoto S; Chen CK; Tada S; Saito H; Shibata R; Sakamoto M; Mori T; Ikeda Y
    Leuk Lymphoma; 2006 Jul; 47(7):1427-30. PubMed ID: 16923586
    [No Abstract]   [Full Text] [Related]  

  • 13. Imatinib mesylate: a new pill for chronic myelogenous leukemia.
    Parmar KK; King RS
    Cancer Pract; 2001; 9(5):263-5. PubMed ID: 11879324
    [No Abstract]   [Full Text] [Related]  

  • 14. Imatinib mesylate causes hypopigmentation in the skin.
    Tsao AS; Kantarjian H; Cortes J; O'Brien S; Talpaz M
    Cancer; 2003 Dec; 98(11):2483-7. PubMed ID: 14635084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib mesylate causes hypopigmentation in the skin.
    Leong KW; Lee TC; Goh AS
    Cancer; 2004 Jun; 100(11):2486-7; author reply 2487-8. PubMed ID: 15160360
    [No Abstract]   [Full Text] [Related]  

  • 16. Imatinib mesylate induced immune thrombocytopenia.
    Rajappa S; Varadpande L; Paul TR; Digumarti R
    Leuk Lymphoma; 2007 Nov; 48(11):2261-3. PubMed ID: 17926182
    [No Abstract]   [Full Text] [Related]  

  • 17. Leukemia. Q&A highlights.
    Frame D; Sessions J; Fausel C
    Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S22. PubMed ID: 18056929
    [No Abstract]   [Full Text] [Related]  

  • 18. Imatinib mesylate.
    Am J Health Syst Pharm; 2001 Dec; 58(23):2241-2. PubMed ID: 11765724
    [No Abstract]   [Full Text] [Related]  

  • 19. Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate.
    Rousselot P; Larghero J; Raffoux E; Calvo F; Tulliez M; Giraudier S; Rybojad M
    Br J Haematol; 2003 Mar; 120(6):1091-2. PubMed ID: 12648085
    [No Abstract]   [Full Text] [Related]  

  • 20. Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate.
    Ohnishi K; Sakai F; Kudoh S; Ohno R
    Leukemia; 2006 Jun; 20(6):1162-4. PubMed ID: 16598305
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.